Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Satellos Bioscience Inc (MSCLF)

Satellos Bioscience Inc (MSCLF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy Business Wire - Tue Dec 9, 6:00AM CST

- Placebo-controlled Phase 2 study will evaluate SAT-3247 treatment over three months among ambulatory children with Duchenne - Study endpoints...

MSCLF : 0.4854 (+1.85%)
MSCL.TO : 0.68 (+3.85%)
Satellos to Participate in December Investor Conferences Business Wire - Tue Nov 25, 6:00AM CST

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSCLF : 0.4854 (+1.85%)
MSCL.TO : 0.68 (+3.85%)
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy Business Wire - Tue Nov 18, 6:00AM CST

Research confirms muscle stem cell dysfunction impairs polarity and impedes production of myogenic progenitors during fetal development Findings solidify...

MSCLF : 0.4854 (+1.85%)
MSCL.TO : 0.68 (+3.85%)
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors Business Wire - Fri Nov 14, 6:00AM CST

Appointed Mark Nawacki, seasoned M&A expert, co-founder, president & former CEO of Searchlight Pharma, to Board of Directors Completed IND submission...

MSCLF : 0.4854 (+1.85%)
MSCL.TO : 0.68 (+3.85%)
Satellos to Participate in November Investor Conferences Business Wire - Thu Oct 30, 6:00AM CDT

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSCLF : 0.4854 (+1.85%)
MSCL.TO : 0.68 (+3.85%)
Satellos to Participate in November Investor Conferences Business Wire - Thu Oct 30, 6:00AM CDT

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSCLF : 0.4854 (+1.85%)
MSCL.TO : 0.68 (+3.85%)
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy Business Wire - Tue Oct 21, 6:00AM CDT

First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled 11-month open-label...

MSCLF : 0.4854 (+1.85%)
MSCL.TO : 0.68 (+3.85%)
Satellos Bioscience Reports Positive Phase 1 Trial Results for Duchenne Muscular Dystrophy Treatment Tipranks - Sat Oct 11, 9:22AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Satellos...

MSCLF : 0.4854 (+1.85%)
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy Business Wire - Fri Oct 10, 8:45AM CDT

Adults with Duchenne muscular dystrophy demonstrated functional improvements exceeding natural history, following 28-day treatment with SAT-3247 ...

MSCLF : 0.4854 (+1.85%)
MSCL.TO : 0.68 (+3.85%)
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress Business Wire - Mon Sep 29, 6:00AM CDT

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSCLF : 0.4854 (+1.85%)
MSCL.TO : 0.68 (+3.85%)

Barchart Exclusives

Protect Your Babies and Your Portfolios with This ‘Strong Buy’ Stock Barchart - 20 minutes ago
Owlet Baby Care (OWLT) has strong technical momentum and is trading at a new 3-year high. Shares are up 200% over the past year. OWLT maintains a 100% “Buy” opinion from Barchart. Wall Street rates OWLT a “Strong Buy,” but Morningstar notes the stock is currently overvalued by 10% after... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot